-- 根據彭博社週三引述知情人士報道，索尼集團（SONY）旗下的索尼音樂即將達成協議，從黑石集團（BX）手中收購包括賈斯汀·比伯和尼爾·楊等藝人作品在內的音樂版權庫。 報道稱，索尼正與新加坡主權財富基金GIC洽談，計劃透過合資企業收購Recognition Music，GIC將支付35億至40億美元。 知情人士告訴彭博社，雙方的目標是在下週完成交易，但能否最終達成尚無定論。 索尼尚未回覆的置評請求。 週三下午交易中，索尼股價上漲超過3%。 （市場動態新聞來自與全球市場專業人士的對話。我們認為這些資訊來自可靠來源，但可能包含傳聞和猜測。準確性無法保證。）
Price: $20.74, Change: $+0.61, Percent Change: +3.06%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%